利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN101037477A 人血清白蛋白与人粒细胞集落刺激因子的融合蛋白的制备方法及产品 无效 - 撤回

人血清白蛋白与人粒细胞集落刺激因子的融合蛋白的制备方法及产品
摘要：
人血清白蛋白与人粒细胞集落刺激因子的融合蛋白的制备方法及产品，属于长效融合蛋白药物技术领域。本发明利用重叠PCR技术，将HSA基因cDNA和G－CSF cDNA进行拼接，中间不加入任何连接肽，得到的HSA－GCSF cDNA融合基因在宿主系统中进行表达，融合基因被整合到宿主的染色体中；本发明的融合蛋白包括与人血清白蛋白至少85％序列同源的第一区和与人粒细胞集落刺激因子至少85％序列同源的第二区，该融合蛋白可以在不改变融合蛋白特性的前提下，进行个别氨基酸残基的取代、缺失或加入；宿主系统可以是细菌、酵母、昆虫细胞、动物细胞、植物细胞等。本发明的融合蛋白在保持了人粒细胞集落刺激因子的生理特性的基础上延长其在体内的半衰期，在药学领域有良好的应用前景。
摘要（英）：

A preparation method and products of a fusion protein of human serum protein and human granulocyte colony stimulating factor belongs to long life fusion protein medicine technical field. The invention splits joint the HSA gene cDNA and G-CSF cDNA by overlap PCR with any linking peptide. The HSA-GCSF cDNA fusion gene is expressed in the host system and is integrated into the host chromosome. The inventive fusion protein consists of a first section which has at least 85% sequence homologous to the human serum protein and a second section which has at least 85% sequence homologous to the human granulocyte colony stimulating factor. The protein can do the substitution, deletion or addition of individual amine acid without changing the characteristics of the fusion protein. The host system can be bacteria, yeast, insect cell, animal cell or plant cell. The inventive fusion protein keeps the physiological property of the human granulocyte colony stimulating factor and prolongs to the half life in vivo and has a good application prospect in the pharmaceutical field.

0/0